Test Details
Methodology
Enzymatic
Result Turnaround Time
Within 1 day
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Test Includes
Cholesterol, total; high-density lipoprotein (HDL); non-HDL cholesterol (calculated as total cholesterol minus HDL); LDL cholesterol (calculated); triglycerides
Use
Assessment of cardiovascular health and risk stratification in pediatric, adolescent, and young adult populations
Special Instructions
State patient's age and sex on the test request form.
Limitations
Patients with obstructive liver disease may develop lipoprotein abnormalities.
Custom Additional Information
Atherosclerosis begins in youth, and this process, from its earliest phases, is related to the presence and intensity of the known cardiovascular risk factors. Clinical events such as myocardial infarction, stroke, peripheral arterial disease, and ruptured aortic aneurysm are the culmination of the lifelong vascular process of atherosclerosis. The most important evidence relating risk in youth to clinical CVD is the observed association of risk factors for atherosclerosis to clinically manifest cardiovascular conditions. Genetic disorders related to high cholesterol are the biological model for risk-factor impact on the atherosclerotic process. Combined evidence from autopsy studies, vascular studies, and cohort studies strongly indicates that abnormal lipid levels in childhood are associated with increased evidence of atherosclerosis. The evidence review supports the concept that early identification and control of dyslipidemia throughout youth and into adulthood will substantially reduce clinical CVD risk beginning in young adult life. Significant evidence exists to indicate that using family history of premature CVD or cholesterol disorders as the primary factor in determining lipid screening for children misses ~30% to 60% of children with dyslipidemias, and accurate and reliable measures of family history are not available. In the absence of a clinical or historic marker, identification of children with lipid disorders that predispose them to accelerated atherosclerosis requires universal lipid assessment. Non-HDL cholesterol level has been identified as a significant predictor of the presence of atherosclerosis, as powerful as any other lipoprotein cholesterol measure in children and adolescents. For both children and adults, non-HDL cholesterol level seems to be more predictive of persistent dyslipidemia and, therefore, atherosclerosis and future events than TC, LDL cholesterol, or HDL cholesterol levels alone. A major advantage of non-HDL cholesterol is that it can be accurately calculated in a nonfasting state and is, therefore, practical to obtain in clinical practice.1
Specimen Requirements
Specimen
Serum (preferred) or plasma
Volume
2 mL
Minimum Volume
0.7 mL (Note: This volume does not allow for repeat testing.)
Container
Red-top tube, gel-barrier tube, or green-top (lithium heparin) tube. Do not use oxalate, EDTA, or citrate plasma.
Collection Instructions
Separate serum or plasma or from cells within 45 minutes of collection.
Storage Instructions
Maintain specimen at room temperature. Stable at room temperature, refrigerated or frozen for seven days.
Patient Preparation
Patient should be on stable diet, ideally for two to three weeks prior to collection of blood, and should fast for 12 to 14 hours before collection of the specimen.
Causes for Rejection
Hemolysis
Footnotes
LOINC® Map
Order Code | Order Code Name | Order Loinc | Result Code | Result Code Name | UofM | Result LOINC |
---|---|---|---|---|---|---|
373632 | Pediatric Lipid Panel, Fasting | 001065 | Cholesterol, Total | mg/dL | 2093-3 | |
373632 | Pediatric Lipid Panel, Fasting | 001172 | Triglycerides | mg/dL | 2571-8 | |
373632 | Pediatric Lipid Panel, Fasting | 011817 | HDL Cholesterol | mg/dL | 2085-9 | |
373632 | Pediatric Lipid Panel, Fasting | 012059 | LDL Chol Calc (NIH) | mg/dL | 13457-7 | |
373632 | Pediatric Lipid Panel, Fasting | 011923 | LDL Calc Comment: | N/A | ||
373632 | Pediatric Lipid Panel, Fasting | 011976 | Non-HDL Cholesterol | mg/dL | 43396-1 | |
373632 | Pediatric Lipid Panel, Fasting | 012028 | Comment | 77202-0 | ||
Order Code | 373632 | |||||
Order Code Name | Pediatric Lipid Panel, Fasting | |||||
Order Loinc | ||||||
Result Code | 001065 | |||||
Result Code Name | Cholesterol, Total | |||||
UofM | mg/dL | |||||
Result LOINC | 2093-3 | |||||
Order Code | 373632 | |||||
Order Code Name | Pediatric Lipid Panel, Fasting | |||||
Order Loinc | ||||||
Result Code | 001172 | |||||
Result Code Name | Triglycerides | |||||
UofM | mg/dL | |||||
Result LOINC | 2571-8 | |||||
Order Code | 373632 | |||||
Order Code Name | Pediatric Lipid Panel, Fasting | |||||
Order Loinc | ||||||
Result Code | 011817 | |||||
Result Code Name | HDL Cholesterol | |||||
UofM | mg/dL | |||||
Result LOINC | 2085-9 | |||||
Order Code | 373632 | |||||
Order Code Name | Pediatric Lipid Panel, Fasting | |||||
Order Loinc | ||||||
Result Code | 012059 | |||||
Result Code Name | LDL Chol Calc (NIH) | |||||
UofM | mg/dL | |||||
Result LOINC | 13457-7 | |||||
Order Code | 373632 | |||||
Order Code Name | Pediatric Lipid Panel, Fasting | |||||
Order Loinc | ||||||
Result Code | 011923 | |||||
Result Code Name | LDL Calc Comment: | |||||
UofM | ||||||
Result LOINC | N/A | |||||
Order Code | 373632 | |||||
Order Code Name | Pediatric Lipid Panel, Fasting | |||||
Order Loinc | ||||||
Result Code | 011976 | |||||
Result Code Name | Non-HDL Cholesterol | |||||
UofM | mg/dL | |||||
Result LOINC | 43396-1 | |||||
Order Code | 373632 | |||||
Order Code Name | Pediatric Lipid Panel, Fasting | |||||
Order Loinc | ||||||
Result Code | 012028 | |||||
Result Code Name | Comment | |||||
UofM | ||||||
Result LOINC | 77202-0 |